Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC
Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6).
Leave a Response
You must be logged in to post a comment.
